Endocrinology and Nutrition Department, Université Catholique de Louvain, Avenue Hippocrate 54, B-1200 Woluwe-Saint-Lambert, Brussels, Belgium.
Curr Med Res Opin. 2010 Feb;26(2):445-54. doi: 10.1185/03007990903500565.
Surveys evaluating plasma lipid goal attainment in patients with coronary heart disease have shown that hypercholesterolaemia is inadequately treated. Limited data account for the reasons behind this. The aim of the CEntralized Pan-European survey on tHE Under-treatment of hypercholeSterolaemia (CEPHEUS) survey was to evaluate the current use and efficacy of lipid-lowering drugs (LLD), and to identify possible patient/physician characteristics associated with failure to achieve low-density lipoprotein cholesterol (LDL-C) targets recommended by the 2003 European guidelines (Third Joint Task Force).
CEPHEUS was a European, multi-centre, cross-sectional survey conducted in eight countries and involved patients on LLD for >3 months (stable medication >6 weeks). One visit was scheduled for data collection, including fasting lipids. In all but one country, physicians and patients filled in a questionnaire about aspects of hypercholesterolaemia and treatment.
Of the 15 199 patients recruited, 14 478 were included in the final analyses. The mean age was 63.2 years, and 45% of patients were female. Overall, 55.3% of the patients achieved their LDL-C target. In multivariate analyses, the factors identified as positive predictors for achieving LDL-C goals included normal body mass index, not smoking, not having metabolic syndrome, being on statin therapy and good treatment adherence.
The population was a selected group of subjects treated with LLD, and the results cannot be extrapolated to the general population. Patient consent was obtained, which may have selected more motivated patients and induced a positive bias. The physician and patient questionnaires were not validated, but were only used for exploratory purposes.
Only 55.3% of patients using LLD achieved the LDL-C target recommended in the 2003 European guidelines.
评估冠心病患者血浆脂质目标达标情况的调查显示，高胆固醇血症治疗不足。有限的数据说明了造成这种情况的原因。集中泛欧调查高胆固醇血症治疗不足（CEPHEUS）的目的是评估降脂药物（LLD）的当前使用情况和疗效，并确定与未能达到 2003 年欧洲指南（第三次联合工作组）推荐的低密度脂蛋白胆固醇（LDL-C）目标相关的可能的患者/医生特征。
CEPHEUS 是一项在八个国家进行的欧洲多中心、横断面调查，涉及使用 LLD 超过 3 个月（稳定用药 >6 周）的患者。计划进行一次就诊以收集数据，包括空腹血脂。除了一个国家，医生和患者都填写了一份关于高胆固醇血症和治疗方面的问卷。
在纳入的 15199 名患者中，14478 名患者被纳入最终分析。患者的平均年龄为 63.2 岁，45%为女性。总体而言，55.3%的患者达到了 LDL-C 目标。多变量分析显示，实现 LDL-C 目标的正面预测因素包括正常体重指数、不吸烟、无代谢综合征、接受他汀类药物治疗和良好的治疗依从性。
该人群为接受 LLD 治疗的特定亚组，结果不能外推至一般人群。获得了患者同意，这可能选择了更有动力的患者，并产生了积极的偏见。医生和患者的问卷未经验证，仅用于探索性目的。
只有 55.3%使用 LLD 的患者达到了 2003 年欧洲指南推荐的 LDL-C 目标。
